Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

China Resources Pharmaceutical to Acquire 23.5% Stake in Lier Chemical to Advance Synthetic Biology Pipeline

Fineline Cube Jul 16, 2026
Company Deals

Braveheart Bio Files IPO Prospectus with Nasdaq for $1.8B Cardiac Myosin Inhibitor Asset

Fineline Cube Jul 16, 2026
Company Deals

WuXi Biologics Enters CDRMO Partnership with CANbridge Through 2028

Fineline Cube Jul 16, 2026
Company Deals

Innovent Biologics Secures $1.1B Global CD40L Antibody Deal with Spero Therapeutics

Fineline Cube Jul 15, 2026
Company Deals

Hansoh Pharmaceutical Secures $2.3B IL-23 Deal and Strategic Stake in Avere-NextCure Merger

Fineline Cube Jul 15, 2026
Policy / Regulatory

China’s CDE Releases Draft Guideline for Real-World Evidence-Based Pediatric Indication Expansion of Marketed Drugs

Fineline Cube Jul 16, 2026
Company Drug

InnoCare Pharma’s Soficitinib Meets Primary Endpoint in Phase III Atopic Dermatitis Trial as Highly Selective TYK2 Inhibitor

Fineline Cube Jul 16, 2026
Company Drug

Amoytop Biotech Secures NMPA Clinical Trial Approval for ACT201, Novel ASO Therapy for Chronic Hepatitis B

Fineline Cube Jul 16, 2026
Company

Sandoz’s Q4 2024 Results Show Strong Biosimilar Growth

Fineline Cube Mar 6, 2025

Switzerland-headquartered Sandoz (SWX: SDZ) has released its Q4 2024 financial results. The firm’s global revenues...

Company Medical Device

Peijia Medical Completes First Two Implants of Trilogy THV System in Taiwan

Fineline Cube Mar 6, 2025

China’s Peijia Medical Ltd (HKG: 9996) announced the completion of the first two implant surgeries...

Company Medical Device

Huadong Medicine’s V30 Optical Radiofrequency Device Receives NMPA Review Approval

Fineline Cube Mar 6, 2025

China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that the National Medical Products Administration (NMPA)...

Company Deals

Jiangsu Nhwa Pharmaceutical Invests in NeuroThree to Develop CNS Therapies

Fineline Cube Mar 6, 2025

China-based Jiangsu Nhwa Pharmaceutical Co., Ltd (SHE: 002262) announced plans to subscribe to Hong Kong-headquartered...

Company

Bayer Posts Steady Q4 Growth, Pharmaceutical Sales Lead the Way

Fineline Cube Mar 6, 2025

German giant Bayer (ETR: BAYN) has released its Q4 2024 financial results, reporting a 0.7%...

Company

NovoCare Pharmacy Offers Reduced-Cost Wegovy for Cash-Paying Patients

Fineline Cube Mar 6, 2025

Denmark-based Novo Nordisk A/S (NYSE: NVO) has announced the launch of NovoCare Pharmacy, a direct-to-patient...

Company Drug

Antengene’s Xpovio Receives Marketing Approval in Indonesia

Fineline Cube Mar 6, 2025

China-based biopharma Antengene Corp., Ltd (HKG: 6996) announced receiving marketing approval in Indonesia for its...

Company Medical Device

Sino Medical Sciences’ HT Supreme Stent System Gains Vietnamese Marketing Approval

Fineline Cube Mar 6, 2025

China-based Sino Medical Sciences Technology Inc., (SHA: 688108) announced that it has received marketing approval...

Company Deals

Yifan Pharma Secures Rights to Bayer’s Stivarga and Nexavar in China

Fineline Cube Mar 6, 2025

China-based Yifan Pharmaceutical Co., Ltd (SHE: 002019) announced a commercialization agreement with Bayer (ETR: BAYN),...

Policy / Regulatory

Major Policy Directions in China’s Healthcare Arena: A Comprehensive Breakdown

Fineline Cube Mar 6, 2025

In a momentous address at the Third Session of the 14th National People’s Congress on...

Company Drug

RongCan Biotech’s mRNA HPV Vaccine Receives FDA Clinical Approval

Fineline Cube Mar 6, 2025

China-based mRNA specialist RongCan (Shanghai) Biotech Co., Ltd announced that it has received clinical approval...

Company Deals

Insilico Medicine and Tenacia Partner on AI-Driven CNS Therapies

Fineline Cube Mar 6, 2025

China’s generative artificial intelligence (AI)-driven biotech Insilico Medicine has formed a partnership with compatriot firm...

Company Deals

Lexenpharm and Sun-Novo Partner on Long-Acting Asthma and COPD Drugs

Fineline Cube Mar 6, 2025

China-based Lexenpharm has formed a partnership with compatriot firm Beijing Sun-Novo Pharmaceutical Research Co., Ltd...

Company Deals

Baheal Pharmaceutical Gains Exclusive Rights to Roche’s MabThera in China

Fineline Cube Mar 6, 2025

China-based health services and distribution giant Baheal Pharmaceutical Group (SHE: 301015) last month reached an...

Company Drug

Zhejiang Huahai’s HB0034 Meets Primary Endpoint in GPP Study

Fineline Cube Mar 6, 2025

China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) announced that its multi-center, double-blinded, randomized, placebo-parallel...

Company Deals

CStone Pharmaceuticals and SteinCares Ink Licensing Deal for PD-L1 Inhibitor in Latin America

Fineline Cube Mar 6, 2025

China-based CStone Pharmaceuticals (HKG: 2616) and Costa Rica-based drug maker and distributor SteinCares have entered...

Company Drug

Fosun Pharma’s 24-Valent Pneumococcal Vaccine Receives NMPA Approval for Phase I Trial

Fineline Cube Mar 6, 2025

China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd’s (SHA: 600196, HKG: 2196) subsidiary Fosun Adgenvax (Chengdu)...

Company Deals

Bio-Thera Solutions Inks Licensing Deal with World Medicine for BAT2206

Fineline Cube Mar 5, 2025

China-based Bio-Thera Solutions (SHA: 688177) has entered into a licensing agreement with World Medicine, granting...

Company Deals

Hainan Poly Pharm’s US Partner Slate Run Pharmaceuticals Collaborates with Premier on Contrast Agents

Fineline Cube Mar 5, 2025

China-based Hainan Poly Pharm Co., Ltd (SHE: 300630) announced a significant partnership between its US...

Company Deals

Gensaic and Novo Nordisk Team Up to Develop Cardiometabolic Therapies

Fineline Cube Mar 5, 2025

US-based AI-powered biotech Gensaic, Inc. announced the signing of a licensing and discovery cooperation agreement...

Posts pagination

1 … 231 232 233 … 696

Recent updates

  • InnoCare Pharma’s Soficitinib Meets Primary Endpoint in Phase III Atopic Dermatitis Trial as Highly Selective TYK2 Inhibitor
  • Amoytop Biotech Secures NMPA Clinical Trial Approval for ACT201, Novel ASO Therapy for Chronic Hepatitis B
  • Boehringer Ingelheim Reports 16.2% H1 2026 Sales Growth Driven by JARDIANCE and New Oncology Launches
  • China Resources Pharmaceutical to Acquire 23.5% Stake in Lier Chemical to Advance Synthetic Biology Pipeline
  • Harbour BioMed and Kelun-Biotech Secure NMPA IND Approval for HBM7575/SKB575, Long-Acting Bispecific Antibody for Asthma
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

InnoCare Pharma’s Soficitinib Meets Primary Endpoint in Phase III Atopic Dermatitis Trial as Highly Selective TYK2 Inhibitor

Company Drug

Amoytop Biotech Secures NMPA Clinical Trial Approval for ACT201, Novel ASO Therapy for Chronic Hepatitis B

Company

Boehringer Ingelheim Reports 16.2% H1 2026 Sales Growth Driven by JARDIANCE and New Oncology Launches

Company Deals

China Resources Pharmaceutical to Acquire 23.5% Stake in Lier Chemical to Advance Synthetic Biology Pipeline

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.